title: Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.
abstract: Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.
authors.affiliation: Department of Gastroenterology, Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: A
authors.initials: A
authors.lastname: Brzezinski
authors.forename: G B
authors.initials: GB
authors.lastname: Rankin
authors.forename: D L
authors.initials: DL
authors.lastname: Seidner
authors.forename: B A
authors.initials: BA
authors.lastname: Lashner
mesh_terms: D000284:Administration, Oral; D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D019804:Mesalamine
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001391:Azo Compounds; D003692:Delayed-Action Preparations; D019804:Mesalamine